Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Trial Identifier: RDEA594-504
Sponsor: Ardea Biosciences, Inc.
NCTID:: NCT03272425
Start Date: August 2017
Primary Completion Date: October 2017
Condition: Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English translation
Portuguese translation

Trial Locations

Country Location
Brazil, Sao Paulo Campinas, Sao Paulo, Brazil